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Abstract 
Background :  To study the pattern of bacterial  
isolates in slow resolving pneumonia (SRP) patients 
Methods : In this  prospective study patients 
(n=121)  fulfilling the criteria of slow resolving 
pneumonia, having Age > 14 years and radiological 
evidence of consolidation were included in the 
study.  Patients having Age > 65 < 14 years, not 
giving consent for Invasive investigation, 
nosocomial pneumonia, atypical pneumonia, fungal 
and mycobacterial infections were excluded. All 
patients were  investigated with multiple view Chest 
X-ray, sputum smear for Gram staining, ZN-staining, 
cytology & culture sensitivity for pyogenic and 
fungal infections. Fiber-optic Bronchoscopy and BAL 
analysis was utilized. Contrast enhanced CT scan 
was employed for accurate definition of the lesion.   
Samples were sent for microbiological evaluation.  
Result:  Age group was 14-65 years with median age 
53 years. One hundred and twenty one pyogenic 
bacterial isolates were obtained. Gram negative 
bacteria were 66.11% while gram positive bacteria 
were 30.57 %  and mixed growth were seen in 3.30%.  
Conclusion : Gram  negative etiology 
predominates in SRP cases with pseudomonas at the 
top followed by klebsiella. 
Key Words: Slow Resolving Pneumonia (SRP), 
Empiric Therapy, Bacterial isolates , Community 
Acquired Pneumonia (CAP). 
 
Introduction 
A slowly resolving pneumonia (SRP) is a real 
challenge in pulmonology practice.10-20% of patients 
admitted in a chest unit belong to this entity.  
Bacteriologic causes are unusual organisms, resistant 
pathogens, inadequate antibiotics, infectious 
complications, or incorrect diagnosis. Due to its high 
mortality, it is essential to recognize these patients and 
treat adequately to reduce the mortality. SRP is in 
reality a clinical dilemma, affecting 10-15% patients of 
the CAP. The majority of CAP patients respond 
rapidly to conventional antibiotic therapy without 
developing any complications.1,2 Microbiological 
samples become negative quickly after antibiotic 
therapy & biomarkers such as C-reactive protein settle 
down.3  A complete recovery requires several weeks or 
even months,  but 10-15 % cases fail to respond to 
empirical treatment. 4-6  The mortality rate in such 
cases remains substantially increased 5-15% despite 
recent advances in clinical care. 1-3  Once slow-
response is recognized, patients are subjected to a full 
re-evaluation process, including microbiological 
testing, X- Ray chest, consideration of further imaging, 
and the spectrum of antibiotics is increased if drug 
resistant pathogens are suspected. On detecting the 
micro-organism, a narrow spectrum is the drug of 
choice. 
It is very difficult to categorize the patient as a case of 
SRP because this lacks uniformity in definition.7. 
Amberson was the first to describe this entity as 
protracted pneumonia in 1943.8  Richard Interbauer, 
defined it as less than 50% clearance at two weeks or 
less than complete resolution at four weeks in 
immune-competent patients.9 In 1975, it was defined 
by Hendin, as pulmonary consolidation persisting for 
more than 21 days. In 1991, Kirtland and Winterbauer 
defined slow resolving CAP by radiological criteria as 
< 50% clearance by two weeks or < complete clearance 
by 4 weeks in immuno-competent cases. Usually 10% 
CAP and 60% HAP show inadequate response to 
empirical antibiotics therapy. Fein and Feinsilver 
described it as delayed radiographic improvement .10 
Arancibia F et al stated that most common reasons are 
related to infections.  Such delayed response depends 
upon the category of infecting organism and the 
immunity of the host. 
Common causes are presence of unusual organisms, 
resistant bacteria, inappropriate antibiotics, super 
infections like fungal / mycobacterial disease, co-
morbidities like drug abuse, HIV, DM, smoking etc. 
Defects in immune system, non compliance, incorrect 
diagnosis & diseases which masquerade pneumoni, 
like ILD, malignancy, pulmonary embolism and 
vasculitis can be other important causes .11-13 These 
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cases appear as CAP but show abnormal behavior to 
the standard treatment and are associated with 
substantial increased mortality that is why it is 
essential to identify and manage these cases on 
priority to reduce the morbidity and mortality. 
               
Patients and Methods 
 This prospective study was  conducted over a period 
of 32 months, in the male ward of department of 
pulmonology, Gulab Devi Chest Hospital Lahore from 
January,2014 to August, 2016.Adult-male patients 
(n=121) of CAP, having age > 14 years, with 
radiological signs of consolidation on chest x-ray, 
not showing adequate radiological improvement after 
04-weeks of antibiotics therapy, were included in the 
study. Exclusion Criteria was patients  with age < 14 
years, atypical pneumonia, hospital acquired 
pneumonia, known cases of  mycobacterial disease, 
anaerobic infections, negative sputum bacteriology, 
bronchiectasis, cavitary lesions, empyema,  pleural 
effusion and fungal infections. Hematological and non 
hematological malignancy & congenital lung disorders 
and those not willing for participation in the study or 
invasive investigations were also excluded. Routine 
investigations like complete blood count, blood sugar, 
urea,creatinin & LFTs were done. All patients were re-
investigated with multiple view Chest X-ray, sputum 
smear for Gram staining, ZN-staining, cytology & 
Culture sensitivity for pyogenic and fungal infections. 
Fiber-optic Bronchoscopy and BAL analysis was 
utilized. Contrast enhanced CT scan was employed for 
accurate definition of the lesion. FNAC/biopsy were 
used for sampling after an informed-consent, in 
pertinent cases.   Samples were sent for 
microbiological evaluation. Data was collected, 
tabulated, analyzed and conclusions were drawn by 
statistical interpretation. 
 
Results 
During 32-months period in 121 cases, pyogenic 
bacterial isolates were obtained. Age group was 14—
65 years with median age 53 years. Patients aged 50 
years and more constituted 66.3% of the study 
population. Cough (94.1%) was the commonest 
presenting feature (Table 1) . Smoking (71.90%) was 
the commonest risk factor (Table 2). Total 121 
pyogenic bacterial isolates were obtained. 37 patients 
showed gram positive, 80-cases gram-negative while 
04 cases had mixed bacterial pathogens (Table 3). 
Gram negative bacteria were 66.11% while gram 
positive bacteria were 30.57 %  and mixed growth 
were seen in 3.30%. Strep Pneumoniae (78.3%) was 
commonest in gram positive and Pseudomonas 
(65.0%) was commonest in gram negative(Table 
3).Lung abscess was the commonest complication 
(Tale 4) 
Table 1:   Clinical Features (n=121) 
Clinical feature  Number  Percentage 
Cough  114  94.21  
Fever  107  88.42  
Expectoration 96 79.33 
Weight  Loss  95  78.51  
Dyspnoea  87  71.90  
Smoking  87  71.90  
Hemoptysis  38  31.40  
Clubbing 11 9.09 
 
Table  2:   Frequency of Risk Factors in 121 patients 
Risk factor  Number  Percentage 
Cigarette smoking 87 71.90 
Diabetes Mellitus 44 39.66 
Drug Abusers 18 14.87 
HIV Positive cases 03 2.47 
 
Table 3: Frequency of Bacterial Isolates 
Total Isolates  n = 121 Observed  
cases 
Percentage 
Gram positive isolates 
Strep. Pneumonie        29 78.37% 
Staph. Aureus         05 13.51% 
Strep. Pyogenes 
 
03 8.10% 
Total =  37 *30.57% 
Gram negative isolates 
Pseudomonas 52 65.0% 
Klebsiella 14 17.50% 
Gram negative rods 09 11.25% 
Coliform bacteria 05 6.25% 
Total = 80 *66.11% 
Mixed growth isolates 
Pseudomonas + Staph.  01  25  
Pseudomonas + Strep. Pyogenes.  01  25  
Pseudomonas + Klebsiella.  02  50  
Total =  04 *3.30% 
*Percentage is calculated for 121patients. 
Table 4:  Slow Resolving Pneumonia Patients-
Complications (n=121) 
Complications  Observed Cases  Percentage  
Pl. Effusion   27  22.31  
Lung Abscess  13  10.74  
Empyema 07 5.78 
Pneumothorax 01 0.82 
 
Discussion 
 In study period 1728 CAP patients were admitted.Out 
of these 249 showed slow resolution. 83 cases were 
diagnosed as tuberculosis, 45 cases were of 
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malignancy and 121 cases (7.0% of 1728) were with 
pyogenic etiology. All patients gave history of illness 
of more than 04 weeks.    Because our study was 
conducted in a male department, all included patients 
were adult male. A few studies have  reported that 
male gender may be at greater risk of slow resolving 
pneumonia.14 
In our study, the median age was 53 years and 66.3% 
patients were with age 50 years and above. Elderly age 
itself is a recognized factor for slow resolution. Blasi F 
et al demonstrated the old age itself as a significant 
factor for slow resolution. Jayaprakash et al showed 
84.6% of patients, above 40 years old and  Chaudhuri 
et al reported 80% cases above 40 years of age, with 
slow resolution.14-1.  Gram-negative bacteria 
predominated in elderly while majority of the young 
patients, showed infection by gram positive 
pathogens. 
The most common symptoms in our  study were 
cough (94.21%) followed by fever (88.42%), 
expectoration (79.33%), Weight loss (78.51%), 
Dyspnoea(71.90%) and hemoptysis (31.40%) while 
Kirtland et al. reported cough as commonest 
symptoms (92%) followed by chest pain (38%), 
breathlessness (38%), fever (36%), and haemoptysis 
(28%). Chaudhuri et al showed cough 100%, followed 
by fever 96.6%, hemoptysis 53.5%, chest pain 38.5% 
and shortness of breath in 33.3%. 
Our study showed, 95 cases (78.51%) with significant 
weight loss and low BMI levels. Low body weights are 
associated with lower complement levels and down 
immune system. Devendra Prasad Singh has reported 
malnutrition, general debility and poor social support 
in the elderly, a contributing factor for slow resolution.  
Cigarette Smoking was the most common risk factor 
(71.90 %) in our study.  Jayaprakash et al also reported 
smoking as the most common co-morbidity.16. Other 
co-morbidities were DM (39.66%), 14.87% drug abuse 
and 2.47% HIV infections, cutting down the immune 
system, responsible for slow resolution. We had 09 
cases of alcohol consumers, 06 opium addicts and 03 
cases were of heroin addicts. Drug abuse is a 
documented factor for slow resolution.18-19  
Avijgan has reported DM as a major association in 
delayed resolution.20. Klebsiella pneumoniae was the 
most common etiology in diabetics in our study, also 
reported by literature. Begamy also reported increased 
 occurrence of Klebsiella infection in diabetic 
patients.21 So in the presence of DM, we should expect 
Klebsiella infection and be ready to face slow 
resolution.   
In our study, 76(62.80%) cases showed right sided 
involvement which is comparable to the results 
reported by Boyd DH.22. Although we excluded the 
cases of pleural effusions and cavitary lung lesions at 
the time of inclusion, 27 cases (22.31%) developed 
minimal pleural effusion,13 cases (10.74%) lung 
abscess and 07 cases (5.78%) of empyema were  
identified by contrast enhanced CT,  during the course 
of investigation. One case of pneumothorax was also 
found. These complications are undisputedly a 
recognized factor for delayed resolution, as reported 
by several researchers.23-28  
This study showed 37 cases (30.57%) with gram-
positive etiology. 29 cases (78.37%) with pneumococci, 
05 cases (13.51%) of  Staph aureus, while 3 cases 
(8.10%) were with Strep. pyogenes etiology. Our study 
shows the pneumococcal predominance in gram 
positive spectrum which is the normal bacteriologic 
behavior towards CAP in immuno-competent patients 
but when there is an immune deficiency  and 
associated co-morbidities, these bacteria exhibit an 
abnormal behavior – slow resolution. Similarly, Staph. 
aureus and Strep. pyogenes are already well-known 
for slow resolution by nature.25, 29-32 
    
Conclusions  
1.Slow Resolving Pneumonia is a practical challenge in 
daily pulmonology practice. After identification, these 
cases must be dealt by considering bacteriology, host 
factors and infective complications.  
2.The antibiotic cover, in slow resolving pneumonias,  
must include against pseudomonas and Klebsiella in 
addition to conventional gram-positive cover, so as to 
enhance resolution and reduce the morbidity and 
mortality. 
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